Abstract:Retinal neovascularization (NV) due to retinal ischemia remains one of the principal causes of vision impairment in patients with ischemic retinal diseases. We recently reported that periostin (POSTN) may play a role in the development of preretinal fibrovascular membranes, but its role in retinal NV has not been determined. The purpose of this study was to examine the expression of POSTN in the ischemic retinas of a mouse model of oxygen-induced retinal NV. We also studied the function of POSTN on retinal NV … Show more
“…IL-13 is an important type 2 T helper (Th2) cytokine controlling biological functions in tissue remodeling such as angiogenesis and fibrosis [34][35][36][37] . We previously found IL-13 up-regulation in the vitreous humors of PDR patients and OIR mice retinas, which suggests that ischemic injury induces IL-13 expression and secretion in the retina 19,31 . Meanwhile, after central nervous system (CNS) injury by stroke, a shift towards Th2 response and downregulation of Th1 response play a role in tissue remodeling during CNS wound healing response 38 .…”
Section: Discussionmentioning
confidence: 90%
“…Our group subsequently demonstrated that PN and TNC were highly up-regulated in the vitreous humor of patients with PDR and proliferative vitreoretinopathy, and promoted both retinal angiogenesis and fibrosis in the pathogenesis of vitreoretinal diseases [17][18][19][20] . Accumulated evidence suggest that ECM components including PN, TNC and fibronectin (FN) that is a well-characterized molecule, promotes physiological and pathological retinal angiogenesis [21][22][23][24][25][26] .…”
ischemic proliferative retinopathy (ipR), such as proliferative diabetic retinopathy (pDR), retinal vein occlusion and retinopathy of prematurity is a major cause of vision loss. our previous studies demonstrated that periostin (pn) and tenascin-c (tnc) are involved in the pathogenesis of ipR. However, the interactive role of pn and tnc in angiogenesis associated with ipR remain unknown. We found significant correlation between concentrations of PN and TNC in PDR vitreous humor. mRNA and protein expression of PN and TNC were found in pre-retinal fibrovascular membranes excised from PDR patients. Interleukin-13 (IL-13) promoted mRNA and protein expression of PN and TNC, and coimmunoprecipitation assay revealed binding between pn and tnc in human microvascular endothelial cells (HRECs). IL-13 promoted angiogenic functions of HRECs. Single inhibition of PN or TNC and their dual inhibition by siRnA suppressed the up-regulated angiogenic functions. pathological pre-retinal neovessels of oxygen-induced retinopathy (oiR) mice were attenuated in pn knockout , tnc knockout and dual knockout mice compared to wild-type mice. Both in vitro and in vivo, pn inhibition had a stronger inhibitory effect on angiogenesis compared to TNC inhibition, and had a similar effect to dual inhibition of pn and tnc. furthermore, pn knockout mice showed scant tnc expression in pre-retinal neovessels of OIR retinas. Our findings suggest that interaction of PN and TNC facilitates pre-retinal angiogenesis, and PN is an effective therapeutic target for IPR such as PDR.
“…IL-13 is an important type 2 T helper (Th2) cytokine controlling biological functions in tissue remodeling such as angiogenesis and fibrosis [34][35][36][37] . We previously found IL-13 up-regulation in the vitreous humors of PDR patients and OIR mice retinas, which suggests that ischemic injury induces IL-13 expression and secretion in the retina 19,31 . Meanwhile, after central nervous system (CNS) injury by stroke, a shift towards Th2 response and downregulation of Th1 response play a role in tissue remodeling during CNS wound healing response 38 .…”
Section: Discussionmentioning
confidence: 90%
“…Our group subsequently demonstrated that PN and TNC were highly up-regulated in the vitreous humor of patients with PDR and proliferative vitreoretinopathy, and promoted both retinal angiogenesis and fibrosis in the pathogenesis of vitreoretinal diseases [17][18][19][20] . Accumulated evidence suggest that ECM components including PN, TNC and fibronectin (FN) that is a well-characterized molecule, promotes physiological and pathological retinal angiogenesis [21][22][23][24][25][26] .…”
ischemic proliferative retinopathy (ipR), such as proliferative diabetic retinopathy (pDR), retinal vein occlusion and retinopathy of prematurity is a major cause of vision loss. our previous studies demonstrated that periostin (pn) and tenascin-c (tnc) are involved in the pathogenesis of ipR. However, the interactive role of pn and tnc in angiogenesis associated with ipR remain unknown. We found significant correlation between concentrations of PN and TNC in PDR vitreous humor. mRNA and protein expression of PN and TNC were found in pre-retinal fibrovascular membranes excised from PDR patients. Interleukin-13 (IL-13) promoted mRNA and protein expression of PN and TNC, and coimmunoprecipitation assay revealed binding between pn and tnc in human microvascular endothelial cells (HRECs). IL-13 promoted angiogenic functions of HRECs. Single inhibition of PN or TNC and their dual inhibition by siRnA suppressed the up-regulated angiogenic functions. pathological pre-retinal neovessels of oxygen-induced retinopathy (oiR) mice were attenuated in pn knockout , tnc knockout and dual knockout mice compared to wild-type mice. Both in vitro and in vivo, pn inhibition had a stronger inhibitory effect on angiogenesis compared to TNC inhibition, and had a similar effect to dual inhibition of pn and tnc. furthermore, pn knockout mice showed scant tnc expression in pre-retinal neovessels of OIR retinas. Our findings suggest that interaction of PN and TNC facilitates pre-retinal angiogenesis, and PN is an effective therapeutic target for IPR such as PDR.
“…We found that BLT1 + cells infiltrated into the periphery of the macular drusen, a common early sign of AMD, and choroidal capillaries in the RPE-choroid of diabetic human eyes but not in nondiabetic human eyes. Recent studies show that infiltrated macrophages exhibit M2-phenotype, which accelerate neovascularization to promote tissue repair in the injured retina of retinopathy (38,79,89,90). Hence, the BLT1 may be a promising therapeutic target for CNV of several diseases, including wet AMD.…”
Age-related macular degeneration (AMD), a progressive chronic disease of the central retina, is associated with aging and is a leading cause of blindness worldwide. Here, we demonstrate that leukotriene B4 (LTB4) receptor 1 (BLT1) promotes laser-induced choroidal neovascularization (CNV) in a mouse model for wet-type AMD. CNV was significantly less in BLT1-deficient (BLT1-KO) mice compared with BLT1-WT controls. Expression of several proangiogenic and profibrotic factors was lower in BLT1-KO eyes than in BLT1-WT eyes. LTB4 production in the eyes was substantially increased in the early phase after laser injury. BLT1 was highly expressed in M2 macrophages in vitro and in vivo, and ocular BLT1+ M2 macrophages were increased in the aged eyes after laser injury. Furthermore, M2 macrophages were rapidly attracted by LTB4 and subsequently produced VEGF-A- through BLT1-mediated signaling. Consequently, intravitreal injection of M2 macrophages augmented CNV formation, which was attenuated by BLT1 deficiency. Thus, laser-induced injury to the retina triggered LTB4 production and attracted M2 macrophages via BLT1, leading to development of CNV. A selective BLT1 antagonist (CP105696) and 3 LTB4 inhibitors (zileuton, MK-886, and bestatin) reduced CNV in a dose-dependent manner. CP105696 also inhibited the accumulation of BLT1+ M2 macrophages in the laser-injured eyes of aged mice. Together, these results indicate that the LTB4-BLT1 axis is a potentially novel therapeutic target for CNV of wet-type AMD.
“…This gap increases bleeding and causes hyperplasia and pathological changes, which leads to irreversible damage to the structure and function of the eye, ultimately resulting in a serious decline in vision and potentially blindness. Keratitis is a common eye disorder that often leads to the formation of new blood vessels ( 5 , 6 ). Paxillin (PXN) is a focal adhesion protein, and is comprised of an LD motif (containing the consensus peptide sequence LDXLLXXL), a conserved cysteine-rich domain comprising of ~60 amino acids with seven conserved cysteine residues and a histidine residue (LIM domain), Src homology 2 (SH2) domain and Src homology 3 (SH3) domains ( 7 ).…”
Neonatal vascular ophthalmopathy is a refractory ophthalmologic disease, and is a major cause of blindness. Occurrence of neonatal vascular ophthalmopathy may be associated with Paxillin, a cellular adhesion molecule which promotes the migration of endothelial cells and angiogenesis. To explore the role of PXN in corneal angiogenesis, human umbilical vein endothelial cells were divided into five groups: i) Control group; ii) Empty vector-transfected control group; iii) PXN knockdown group (shPXN group); iv) PXN-negative control (NC) group; and v) PXN over-expressed group (overExp group). PXN protein levels, migration and tube formation were assessed in the different experimental groups. Mice were divided into four groups: i) Control; ii) Model; iii) shPXN; and iv) overExp groups. Tube formation was significantly increased in the overExp group compared with the empty vector-transfected control group (P<0.01). Tube formation was significantly decreased in the shPXN group compared with the PXN-NC group (P<0.01). In mice, blood corpuscles were significantly decreased in the shPXN group. PXN promoted the migration of endothelial cells and corneal angiogenesis. The results of the present study suggest a role for PXN in corneal angiogenesis and provide a theoretical basis and potential target for the treatment of corneal angiogenesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.